RFG Advisory LLC Acquires 25,387 Shares of Viking Therapeutics, Inc. $VKTX

Key Points

• RFG Advisory LLC has increased its holdings in Viking Therapeutics by 64.0%, acquiring an additional 25,387 shares during the second quarter, bringing its total ownership to 65,039 shares valued at $1,724,000.
• Viking Therapeutics received mixed ratings from analysts, with target price estimates ranging from $38.00 to $125.00 and a consensus rating of "Moderate Buy".
• As of the latest trading session, shares of Viking Therapeutics opened at $35.12, having a 12-month range of $18.92 to $81.73 and a market cap of $3.95 billion.

RFG Advisory LLC lifted its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 64.0% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 65,039 shares of the biotechnology company's stock after acquiring an additional 25,387 shares during the quarter. RFG Advisory LLC owned 0.06% of Viking Therapeutics worth $1,724,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. increased its stake in shares of Viking Therapeutics by 121.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company's stock worth $718,000 after buying an additional 16,302 shares during the period. Wealth Management Associates Inc. purchased a new position in shares of Viking Therapeutics in the first quarter worth $241,000. GAMMA Investing LLC increased its stake in shares of Viking Therapeutics by 9,209.9% in the first quarter. GAMMA Investing LLC now owns 24,392 shares of the biotechnology company's stock worth $589,000 after buying an additional 24,130 shares during the period. Kingstone Capital Partners Texas LLC purchased a new position in shares of Viking Therapeutics in the second quarter worth $1,367,000. Finally, U.S. Capital Wealth Advisors LLC increased its stake in shares of Viking Therapeutics by 77.7% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 63,546 shares of the biotechnology company's stock worth $1,684,000 after buying an additional 27,795 shares during the period. 76.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Citigroup lifted their target price on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. BTIG Research reaffirmed a "buy" rating and issued a $125.00 target price on shares of Viking Therapeutics in a research note on Monday, September 22nd. Raymond James Financial reduced their price objective on shares of Viking Therapeutics from $125.00 to $122.00 and set a "strong-buy" rating on the stock in a research report on Thursday, July 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Viking Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $86.42.

Viking Therapeutics Trading Up 6.3%

Shares of Viking Therapeutics stock opened at $35.12 on Thursday. Viking Therapeutics, Inc. has a 12-month low of $18.92 and a 12-month high of $81.73. The company has a market cap of $3.95 billion, a P/E ratio of -22.95 and a beta of 0.64. The company's fifty day simple moving average is $29.33 and its two-hundred day simple moving average is $28.23.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.14). During the same quarter in the previous year, the company posted ($0.20) EPS. The business's revenue for the quarter was up NaN% on a year-over-year basis. Analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.